论文部分内容阅读
阿糖胞苷(Ara-c)作为治疗白血病的主要药物已有几十年的历史。近几年的研究又发现其具有诱导分化作用,即作用于癌细胞后,使其失去本身的性质,具有了类似正常细胞的性状功能等。这一发现使阿糖胞苷在治疗和预防癌症方面有了新的进展。本文将其诱导分化作用与其它分化诱导剂的联合应用及其作用机制和临床应用综述如下。1 阿糖胞苷诱导分化作用的证实Watanabe Tel.等证明,K_(582)细胞株以0.5 μM的Ara-c作用120h,血红素为500pmol/5×10~5细胞而对照组仅为20pmol/5×10~5细胞,同时有45%的细胞呈Bendizine反应阳性。
Cytarabine (Ara-c) has been a leading drug in the treatment of leukemia for decades. In recent years, the study found that it has the induction of differentiation, that is, after acting on cancer cells, so that it loses its own nature, with a similar normal cell traits and so on. This discovery has led to cytarabine in the treatment and prevention of cancer has made new progress. This article will be its induction of differentiation and other differentiation inducer combination and its mechanism of action and clinical application are summarized below. 1 cytarabine induced differentiation proved Watanabe Tel. And so on, K_ (582) cell line with 0.5 μM Ara-c effect 120h, hemoglobin 500pmol / 5 × 10 ~ 5 cells in the control group was only 20 pmol / 5 × 10 ~ 5 cells, while 45% of cells were positive for Bendizine reaction.